PHARMACEUTICAL INDUSTRY & EFFICACY MODELS
Our laboratories in Saint-Malo also develop customised models to meet your specific needs.
Oncology
Cancer being a leading cause of death worldwide, the development of new cancer therapies is a major challenge for the pharmaceutical industry.
For Proofs of Concept (POCs), C.RIS Pharma offers you in vitro models with cancer or normal cell screening and in vivo models with xenografts in immunodeficient mice, syngeneic models in normal wild type mice or rats, chemically induced tumours, and other specific models…
Metabolic diseases
C.RIS Pharma performs in vivo studies to give you an expert answer on the potential efficacy of your molecules in the treatment of metabolic diseases such as hepatic diseases (steatosis, humanized liver models, …), diabetes (transgenic or chemo-induced models) and obesity (transgenic or diet-induced models).
Inflammatory pathologies
We can provide support for the development of your programs against inflammatory pathologies with in vitro test on human keratinocytes exposed to UV-B or with more specific in vivo models (Carrageenan-induced footpad inflammation model, Experimental Autoimmune Encephalomyelitis model for multiple sclerosis, …).
Infectious diseases
C.RIS Pharma offers you a number of tests and models in order to measure the efficacy of your novel therapy in preventing or curing infectious diseases. We perform in vitro screening for antimicrobial activity in agar or liquid media on all bacterial strains to determine the Minimum Inhibitory Concentrations for example.
For in vivo proofs of concept, we have developed 3 models: pneumonia, impetigo, or sepsis induced by Staphylococcus aureus in mice. The survival rate and the bacterial load in targeted organs are observed.
Cardio-vascular diseases
In the cardiovascular therapeutic area, C.RIS Pharma is able to test the efficacy of your cardiac regenerative therapy in a rat ischemia model.
Renal diseases
In the domain of renal diseases, the model of polycystic kidney was recently developed by our team in transgenic mice, and we can also test the efficacy of your regenerative treatment of kidney functions in a mouse ischemia model.
Neurodegenerative models
C.RIS Pharma supplies in vivo POC studies of multiple sclerosis treatment on the Experimental Autoimmune Encephalomyelitis model. Other models may be developed.
Intracerebroventricular administration, intranasal administration and stereotactic surgery options are provided.
Surgical models
In the surgical field, C.RIS Pharma has specific expertise in designing customized models to assess the efficacy of biomaterials or cell-based reconstructive therapies. Various models of surgery can be transferred or set up to meet your specific needs like bone defection or deletion, joint defection, spine fusion and skin injuries. The regeneration with the test substance is monitored and compared to the control group by MRI or immunohistochemistry.
